#United States #San Diego #Clinical Trials #Aethlon Medical #Hemopurifier

Introduction

Aethlon Medical, Inc. has recently published its financial results and an overview of its advancements in cancer treatment technologies for the fiscal second quarter ending September 30, 2025. This update provides a look into Aethlon's operations, newly initiated trials, and the significant improvements in operational efficiency that have been achieved while navigating a challenging healthcare landscape.

Financial Performance

As of September 30, 2025, Aethlon reported a cash reserve of approximately $5.8 million. The company's operational expenses dropped notably by 48% to approximately $1.5 million, compared to the same period in 2024 when expenses were around $2.9 million. This cost reduction reflects Aethlon's commitment to disciplined financial management during its ongoing clinical programs.

• - Payroll and Related Expenses: Decreased by about $778,000, attributed to a reduction in workforce and lower bonus provisions.
• - General and Administrative Expenses: Fell by approximately $437,000, signaling lower trial costs and operational expenditures. A tax incentive also contributed to these savings.
• - Professional Fees: Reduced by $177,000, primarily due to a decrease in investor relations costs, even with increased legal and financial service costs.

Consequently, Aethlon's operating loss for the quarter improved to $1.5 million, a significant decrease from $2.8 million in the previous year's quarter. Other income, which mostly stems from interest on cash reserves, totaled approximately $22,730.

Clinical Trial Advancements

Aethlon has made pivotal steps in its clinical initiatives targeting cancer therapies. The company has seen positive progress with ongoing recruitment for Cohort 2 in their Australian oncology trial that assesses the Hemopurifier® device enhanced by a modified protocol. This trial includes patients receiving combination therapies involving Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®), aiming to evaluate the feasibility and safety of the Hemopurifier.

• - Extracellular Vesicles (EVs) Study: Initial results indicate that the Hemopurifier may effectively reduce the concentration of EVs that contribute to tumor progression and resistance against therapies.
• - Clinical Indicators: Significant improvements in laboratory markers relating to immune response were recorded in multiple participants post-treatment, enhancing the potential therapeutic efficacy.

Collaborative Research

In parallel, Aethlon continues collaboration with the University of California, San Francisco (UCSF) focusing on Long COVID research, assessing the efficacy of the Hemopurifier in patients affected by this condition. A manuscript documenting these findings is anticipated to be published in a peer-reviewed journal soon.

• - Concurrent Study: The Hemopurifier's capability in extracting harmful EVs from patients' circulation showcases its dual potential against both infectious diseases and cancer, emphasizing a novel approach to treating these conditions with a singular device.

Operational Efficiency and Future Goals

Operationally, Aethlon's focus on cost management and strategic investments in research and technology has resulted in reduced expenses without compromising its clinical efforts. CEO James Frakes noted, "Our ongoing trial progress, research collaborations, and technology initiatives continue to support our long-term goal of developing therapeutic solutions for cancer and life-threatening infectious diseases."
Aethlon's operational strategies are aimed at laying the foundational framework for future efficacy trials, with the objective of preparing the Hemopurifier for wider clinical application and potential approval.

Upcoming Conference Call

Management will present further insights into these developments during a conference call scheduled for today, November 12, 2025, at 4:30 PM ET. Interested parties can register online to participate and engage in a Q&A session post-presentation.

Conclusion

Aethlon Medical's commitment to advancing its technology and contributing to cancer treatment through innovative therapies remains robust, as evident in the recent financial results and ongoing clinical trials. With a keen eye on operational efficiency and groundbreaking research, Aethlon is positioned for promising advancements in the medical therapeutic landscape.